18.38 USD
▲-0.31+3.03%
盘后 17.65 -1.07%
2026-08-03
市值
$6.38B
市盈率
—
EPS
-0.96
股息率
—
52 周区间
1.33 – 24.28
成交量
4.76M
Beta
0.65
目标价
22.80
52W 低 1.3352W 高 24.28
价格走势
公司简介
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agre...